Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
We currently have good inventories, but due to possible growth in demand, we need to start increasing our manufacturing capacity, says CEO Markku Jalkanen .
I think amount of the documentation and all kind of due diligence's is enormous for such a short time, even during the pandemic crisis. But referring back to Mr Jalkanen interview to Proactive channel, there are number of parties interested in the company. This may mean anything; however, it is strange that we are not recruiting nor advancing T research/production programs. My best guess is that kind of cooperation news will come during this quarter.
No, I do not believe that Faron is typical Nordic company, where 80% of the staff is enjoying their 5-6 week summer holidays.
Zum,
Maybe the time scale is unrealistic for a deal to be announced, but what if talks have already started and the reason we replaced Panmure was this very deal...
It is more probable that we will see a deal for Clevergen via a partner. It’s true to say that big Pharma are out to spend money and AZN deal today with Redx follows a nice deal with SLN. Those types of licensing deals that also aim to fund phase III imo are more probable.
It’s also helping to limit any downside associated with bad results from Traumakine. Activity over the next 6 months on all fronts has the potential to be transformational.
And again.
- no news on T production
- no news on HIBISCUS advancement
- NO NEWS on other FP-1201 programs
- no reqruitments/open positions
Is the research capcity already exceeded or not?
Could be whole T divested? For focusing C and keep away from the Covid acute issues, saving the team and whole company?
Those questions I have no answer.
Most likely completely wrong questions, but however.
I do not buy either. Where to spend 3bn in the case of vaccines?
ZumZum - Maybe so but lets not forget that Clevegen has the potential to be a Monster! This a message posted a long time a go on this board which i saved..............
If Clevegen is successful, it will be the world’s most sold medicine. If you take for instance colorectal cancer where are clever-1 positive patients over 1 million/year. The revenue from Clevegen would be USD 100 billion/year, if the pricing is USD 100,000/year/patient and that is from the lower end of pricing of these drugs and it should work in other clever-1 positives cancers as well:
https://www.reuters.com/article/us-usa-healthcare-cancer-costs/the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-idUSKBN1750FU
I think the 3 billion bond is more connected to their covid vaccine trials
https://www.google.com/amp/s/amp.insurancejournal.com/news/international/2020/08/03/577696.htm
By me, unrealistic time schedule. Otherwise trading should be immediately suspended for 3-5 trading days.
27th July - Cairn Financial Advisers LLP has been appointed as Nominated Adviser to the Company
4th August - AstraZeneca prices a $3bn bond issue
6th August - AstraZeneca T.O Faron Pharmaceuticals..........................................?!
I’d take that oil!
Terry - Imagine if the $3 Bn bond was to takeover Faron..........that would equate to approx £48.5 a share!!!
Astra Zeneca have an RNS out this morning with a $3 Bn bond offer due to close on 6th Aug issued for ‘general corporate purposes’
Few posts over on SNG board suggesting it could be them, that would be around £20 a share!
It would be nice if it was FARN.
Oilman, you are on the ball my friend.
“This is the unique strength of this trial and soon the findings will be published.”
They seem too confident to come out and say none of the 5 drugs worked.
Article 20 mins old:
In an exclusive interview to ThePrint, India's chief trial coordinator Sheela Godbole says as many as 600 volunteers have been registered & 27 trial sites set up to test 2 treatment drugs.
Treatment Drugs: Even during lockdown, we could quickly import remdesivir and interferon beta 1 a
https://theprint.in/health/this-is-how-india-set-up-whos-drug-solidarity-trial-in-less-than-a-month-despite-lockdown/473741/